Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300390 · ClinicalTrials.gov registry record
Assessment of Endothelial Function, Apolipoproteins and Adiponectin
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 150
- Enrollment target
NCT01300390: Completed study, sponsored by Mayo Clinic.
NCT01300390 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01300390 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
The overall hypothesis is that endothelial function, apolipoprotein levels and adiponectin levels are accurate predictors of underlying cardiovascular disease in patients with end-stage liver disease, in whom standard tools for the diagnosis of and screening for cardiovascular disease are of limited utility.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01300390
The ClinicalTrials.gov registry entry for NCT01300390 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01300390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01300390 about?
NCT01300390 is a clinical study titled "Assessment of Endothelial Function, Apolipoproteins and Adiponectin". The overall hypothesis is that endothelial function, apolipoprotein levels and adiponectin levels are accurate predictors of underlying cardiovascular disease in patients with end-stage liver disease, in whom standard tools for the diagnosis of and screening for cardiovascular disease are of limited...
What is the current status of trial NCT01300390?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2011-06. Estimated completion is 2015-10.
Who is sponsoring clinical trial NCT01300390?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.